A public-private partnership that supports the discovery of new medicines through open access research.
The Structural Genomics Consortium catalyzes research in new areas of human biology and drug discovery by focusing explicitly on less well-studied areas of the human genome.
The Consortium accelerates research in these new areas by making all its research output available to the scientific community with no strings attached, and by creating an open collaborative network of scientists in hundreds of universities around the world and in nine global pharmaceutical companies.
Together, this network of academic and industry scientists is driving a new scientific and drug discovery ecosystem whose primary aim is to advance science and is less influenced by personal, institutional or commercial gain.
Research services are provided for collaborative purposes only.
High throughput protein crystallization, custom screens (SGC-I screen, and Red Wings screen, courtesy of Alexei Savechenko’s group at Structural Proteomics in Toronto).
- Life sciences, pharmaceuticals and medical equipment
Specialized labs and equipment
| Specialized lab | Equipment | Function |
|---|---|---|
| Crystallography Lab | Rigaku FR-E X-ray Generation System | Home source X-ray crystallography for crystal screening and data collection |
Private and public sector research partners
- AbbVie Corporation
- Bayer Inc.
- Boehringer Ingelheim (Canada) Ltd.
- Canada Foundation for Innovation
- Eli Lilly Canada
- São Paulo Research Foundation (FAPESP)
- Genome Canada
- GlaxoSmithKline (GSK) Inc.
- Janssen Pharmaceuticals NV
- Merck Canada Inc.
- Novartis
- The Ontario Ministry of Research and Innovation (MRI)
- Pfizer
- Takeda Pharmaceutical Company Ltd.
- The Wellcome Trust